Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia

Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia

Blog Article

Abstract Background There is an urgent need for highly efficacious antiviral therapies in immunosuppressed hosts who develop coronavirus La inclusión financiera en Sincelejo (Colombia). Un modelo econométrico probit disease (COVID-19), with special concern for those affected by hematological malignancies.Case presentation Here, we report the case of a 75-year-old male with chronic lymphocytic leukemia who was deficient in CD19+CD20+ B-lymphocyte populations due to previous treatment with anti-CD20 monoclonal antibodies.The patient presented with severe COVID-19 pneumonia due to prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and was treated with two courses of the antiviral plitidepsin on a compassionate use basis.

The patient subsequently achieved an undetectable viral load, and his pneumonia resolved.Conclusions Treatment with plitidepsin was well-tolerated without any further hematological or cardiovascular toxicities.This case further supports plitidepsin as a Drancy–La Muette: Concentrationary Urbanism and Psychogeographical Memory in Alexandre Lacroix’s La Muette (2017) potential antiviral drug in SARS-CoV-2 patients affected by immune deficiencies and hematological malignancies.